Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sapacitabine + venetoclax
- Development stage
- Phase 2
- Lead developer
- Bio Green Med Solution
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sapacitabine + venetoclax is an investigational combination therapy for cancer. Sapacitabine is a nucleoside analog prodrug that induces DNA damage and apoptosis in cancer cells by incorporating into DNA and causing strand breaks. Venetoclax is a small molecule BCL-2 inhibitor that promotes apoptosis by binding to the BCL-2 protein, displacing pro-apoptotic proteins, leading to mitochondrial outer membrane permeabilization and activation of caspase enzymes. Venetoclax is approved for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML) in certain populations[1][3][5][8]. The combination aims to enhance anti-tumor activity through complementary mechanisms of inducing cell death.
- Other names
- sapacitabine + venetoclax
02
Targets
BCL-2 (BCL-2 family)DNA
Beyond the preview
Go deeper on sapacitabine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sapacitabine + venetoclax.